Press release
Advancing TCR-based Cell Therapies & Bispecific Approaches
24 April 2024
Cellply at Advanced Therapies Week 2024
Events
Cellply at Advanced Therapies Week 2024
Introducing VivaCyte
At single cell resolution, VivaCyte™ offers a dramatically improved level of understanding of immunotherapy mode of action, including relative potency. Our powerful platform delivers in-depth characterization of immune cell function, including serial killing, in combination with phenotypic analysis.
Taking cell therapy characterization and comparison to a new level.
Join Richard Harbottle and Evren Alici as they present their unique insights on how their labs utilize VivaCyte to rapidly identify the best TCR edits & validate a proprietary nanovector editing system; and hear how single cell characterization of immune cell function can be deployed in translational studies.
Hosted by Massimo Bocchi and Francesco Imperatore, these seminars are part of the formal fringe program of Advanced Therapies Week and open to all those interested in cell therapy characterization. The sessions will be held twice during the meeting so please sign up for the session that fits your timetable.
About Cellply
Based in Bologna, Cellply is the first Italian biotech to enter the market with a platform capable of measuring the effectiveness of cellular immunotherapies in the treatment of oncological diseases, paving the way in the fight against cancer. Thanks to Cellply’s technology, it will be possible to save the lives of even advanced-stage cancer patients through a system that optimizes development costs, controls the quality of cells delivered to the patient, and in the future will allow for monitoring of treated patients.
continue reading
You may also like
Press release
Nature Biotechnology publishes research from DKFZ and Cellply highlighting novel approach for accelerating cellular immunotherapy development
19 March 2024
Events
Dual attendance for Cellply at March’s leading events in the cell therapy industry.
18 March 2024
Events
Launch of VivaCyte® at Advanced Therapies Week 2024
26 January 2024
News
Cellply launches its end-to-end single cell potency characterization platform VivaCyte
17 January 2024
Press release
Cellply concludes a new internal round of €3.6 million and extends the round to new investors!
27 September 2023
News
CellPly announces acceptance of one abstract at the CICON23 conference
18 September 2023
Press release
CellPly announces Emiliano Spagnolo as the new CEO
27 July 2023
News
L’innovazione Cellply in un articolo sulla rivista Le Scienze
4 March 2020
Events
Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting
25 November 2019
News
Cellply wins the €300k Gaetano Marzotto prize and Unicredit StartLab prize
22 November 2018
Events
Cellply invited to present at the World Health Summit 2019
22 October 2018
Press release
Cellply secures €2.34m non-dilutive grant funding from the European Commission for a novel precision oncology diagnostic platform
24 May 2018
News
Cellply selected as finalist at Lyfebulb Oncology Award
1 March 2018
Events
Cellply abstract accepted at the AACR 2018 Annual Meeting
4 February 2018
Press release
Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting
4 November 2016
News
Cellply wins an H2020 SME Instrument Phase 1 grant
20 October 2016
Keep in touch
Need some infos?
Drop us a line or give us a ring. We love to hear from you and are happy to answer any questions.